TICKERNERD
Menu
CGTXCGTXHealthcare · Biotechnology

CGTX Stock Forecast: Cognition Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.00
+4.49% on the day

The 3 Wall Street analysts covering Cognition Therapeutics, Inc. hold a median 12-month price target of $3 — +200.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$94.7M
Ticker Nerd rank
39 / 100
Median analyst target
$3.00
Analysts covering
3
Total return, dividends reinvested
1W
−1.0%
1M
−0.0%
YTD
−25.9%
1Y
−49.8%
From 52W high
−68.6%
From 52W low
+68.0%
$0.60
$3.18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CGTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cognition Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
39 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
81
Size
76
Revisions
71
Momentum
43
Quality
36
Value
30
Accruals
29
Issuance
22
Volatility
10

Growth (81): Sales and profits are climbing, and climbing faster than before.

Volatility (10): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CGTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CGTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26CGTXHigh $4.00Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $3.00Median $3.00High $4.00

The green dot is the last close — the median target sits +200.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Mar 2026Chardan CapitalMaintainsBuy$4.00
4 Dec 2025HC Wainwright & Co.ReiteratesBuy—
21 Nov 2025B. Riley SecuritiesReiteratesBuy—
19 Nov 2025HC Wainwright & Co.ReiteratesBuy—
8 Aug 2025Chardan CapitalMaintainsBuy—
26 June 2025HC Wainwright & Co.ReiteratesBuy—
27 May 2025HC Wainwright & Co.MaintainsBuy—
8 May 2025Chardan CapitalMaintainsBuy—
24 Mar 2025HC Wainwright & Co.MaintainsBuy—
21 Mar 2025Chardan CapitalMaintainsBuy—
26 Feb 2025Chardan CapitalMaintainsBuy—
19 Dec 2024B. Riley SecuritiesUpgradeBuy—
19 Dec 2024Chardan CapitalMaintainsBuy—
19 Dec 2024HC Wainwright & Co.MaintainsBuy—
27 Nov 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024Chardan CapitalMaintainsBuy—
4 Nov 2024HC Wainwright & Co.ReiteratesBuy—
31 Oct 2024Chardan CapitalMaintainsBuy—
12 Aug 2024HC Wainwright & Co.MaintainsBuy—
6 Aug 2024B. Riley SecuritiesDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CGTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CGTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Cognition Therapeutics, Inc. (CGTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.1×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
2.9×

Cheaper than 36% of US stocks

EV / EBITDA
−1.7×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−83.8%

Higher than 15% of US stocks

Return on assets
−78.2%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CGTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CGTXCognition Therapeutics, Inc.$94.7M
39
ACRVAcrivon Therapeutics, Inc.$94.6M
68
FBIOFortress Biotech, Inc.$95.3M
78
BMEABiomea Fusion, Inc.$96.9M
50
YARWYarrow Bioscience, Inc.$97.2M
51
PYPDPolyPid Ltd.$97.3M
50
ATRAAtara Biotherapeutics, Inc.$97.4M
65

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cognition Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CGTX news & analysis

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 7 Aug 2026positive

Cognition Therapeutics (CGTX) reported a second-quarter loss of $0.04 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and improved from the $0.11 per-share loss a year earlier.

Why it matters — A CGTX watcher would care because the narrower-than-expected loss shows the company beat analyst estimates and improved its bottom line versus the same quarter last year.

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

GlobeNewsWire · 6 Aug 2026neutral

Cognition Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2026, and provided an accompanying business update. The announcement was made via press release on August 6, 2026.

Why it matters — CGTX watchers track quarterly results and business updates to assess the clinical-stage company's financial position and progress in developing treatments for neurodegenerative disorders.

FAQ

Frequently asked questions about CGTX stock

What is the CGTX stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Cognition Therapeutics, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CGTX stock a buy right now?

Of the 3 analysts covering Cognition Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cognition Therapeutics, Inc. 39 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CGTX?

As at 22 Aug 2026, Cognition Therapeutics, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (81 of 100).

Will CGTX stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +200.1% from the last close, and Ticker Nerd's factor model ranks Cognition Therapeutics, Inc. 39 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CGTX stock forecast for 2030?

No analyst covering Cognition Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.

How has CGTX stock performed over the past year?

Cognition Therapeutics, Inc. returned -49.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cognition Therapeutics, Inc. do?

Cognition Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina.

What is the latest news on CGTX?

The most recent item we track (Zacks Investment Research, 7 Aug 2026): "Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates". Cognition Therapeutics (CGTX) reported a second-quarter loss of $0.04 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and improved from the $0.11 per-share loss a year earlier.

Company

About Cognition Therapeutics, Inc.

Cognition Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. Its lead candidate, zervimesine (also known as CT1812), is an investigational oral small molecule designed to penetrate the blood-brain and blood-retina barriers, selectively bind to the sigma-2 receptor complex, and restore normal neuronal functions such as autophagy, cholesterol biosynthesis, vesicle trafficking, and protein stabilization. The company is advancing zervimesine through clinical programs in Alzheimer’s disease, including mild-to-moderate and early stages, as well as dementia with Lewy bodies and geographic atrophy secondary to dry age-related macular degeneration. These efforts encompass Phase 2 and planned Phase 3 studies evaluating safety, tolerability, cognition, function, and neuropsychiatric outcomes, alongside expanded access programs. Founded in 2007 and headquartered in Purchase, New York, Cognition Therapeutics Inc. plays a role in addressing unmet needs in neurodegenerative and neuro-ophthalmic diseases by modulating cellular damage response mechanisms.

CEO Ms. Lisa Ricciardi · 14 employees · United States · https://www.cogrx.com